Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients

Nephron - Clinical Practice

Volumn 112, Issue 4, 2009, Pages

  Furuya, Ryuichi ^a   Kumagai, Hiromichi ^b   Odamaki, Mari ^b   Takahashi, Masaaki ^c   Miyaki, Asumi ^a   Hishida, Akira ^c  

^a Iwata City Hospital   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced oxidation protein products; Pentosidine; Peritoneal dialysis; Residual renal function

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; CARBONYL DERIVATIVE; MALATHION; PENTOSIDINE;

ADULT; ARTICLE; CHEMICAL STRESS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRESERVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; URINALYSIS; URINE VOLUME;

ARGININE; BLOOD PROTEINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LYSINE; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PERITONEAL DIALYSIS; REACTIVE OXYGEN SPECIES; RECOVERY OF FUNCTION;

EID: 67449149589     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224792     Document Type: Article

References (31)

1. Bargman JM, Thorpe KE, Churchill DN, for the CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
2. Rocco MV, Frankenfield DL, Prowant B, Frederick P, Flanigan MJ: Risk factors for early mortality in US peritoneal dialysis patients: impact of residual renal function. Pert Dial Int 2002; 22: 371-379.
3. Termoeschulzen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Kredit RT, for the NECOSAD Study Group: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-1302.
4. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui S, Li PK: Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20: 396-403.
5. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, for the Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
6. Szeto C, Wong TY, Leung C, Wang AY, Law M, Lui S, Li PK: Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400-407.
7. Szeto C, Wong TY, Chow K, Leung C, Li PK: Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003; 18: 977-982.
8. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, on behalf of the CREED investigators: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
9. Wang AY, Wang M, Woo J, Law M, Chow K, Li PK, Lui SF, Sanderson JE: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
10. Wang AY, Wang M, Woo J, Lam CW, Lui S, Li PK, Sanderson JE: Inflammation, residual renal function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186-2194.
11. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with endstage renal failure. Kidney Int 1997; 51: 1170-1181.
12. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2004; 45: 39-47.
13. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H: Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004; 43: 690-695.
14. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
15. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in endstage renal disease. Circulation 2002; 106: 2212-2217.
16. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Bárány P, Heimbürger O, Lindholm B: Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006; 66: 418-425.
17. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
18. Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Ayala ER, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614-1622.
19. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunie M, Verger C, Jungers P, Descamps-Latscha B: The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996; 45: 379-382.
20. Zoccali C, Mallamaci F, Asahi K, Benedetto FA, Tripepi G, Tripepi R, Nicocia G, Buemi M, Miyata T: Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 2001; 14: 293-298.
21. Randerson DH, Chapman GV, Farrell PC: Amino acid and dietary status in CAPD patients; in Atkins RC, Farrell PC, Thomson N (eds): Peritoneal Dialysis. Edinburgh, Churchill-Livingstone, 1981, pp 180-191.
22. Takahashi M, Hoshino H, Kushida K, Kawano K, Inoue T: Direct quantification of pentosidine in urine and serum by HPLC with column switching. Clin Chem 1996; 42: 1439-1444.
23. Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C, Kurokawa K: Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53: 416-422.
24. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Kidney Int 1999; 55: 2478-2492.
25. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 512-519.
26. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G, for the HEMO Study Group: Serum β-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study. J Am Soc Nephrol 2006; 17: 546-555.
27. 2-Microglobulin for risk stratification of total mortality in the elderly population. Arch Intern Med 2008; 168: 200-206.
28. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218.
29. Slowik-Zylka D, Safranow K, Dziedziejko V, Dutkiewicz G, Ciechanowaski C, Chlubek D: The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients. J Nephrol 2006; 19: 65-69.
30. ε-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Kidney Int 1998; 54: 1357-1366.
31. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962.